Search in site
BlueWind Medical is an innovative medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has grown to an established company with diverse, creative and committed employees.
BlueWind Medical has successfully completed several clinical studies with excellent results and is focused on bringing this breakthrough RENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market
We will provide safe and effective peripheral neuromodulation solutions for patients suffering from neurological disorders
We are helping patients around the world, initially focusing on tibial nerve modulation by treating pelvic floor disorders, including over-active bladder
Mr. Roy Katz brings to BlueWind Medical more than two decades of global and cross-cultural leadership and business experience in the medical device industry, in both startups and large corporations. Prior to joining BlueWind Medical, Roy served as Vice President for Business Development for Rainbow Medical, a medical device investment firm and technology incubator. Previously, Roy served as marketing director for Rhythmia Medical, a venture-backed medical device startup that was acquired by Boston Scientific in 2012. Prior to joining Rhythmia, Roy held several marketing positions at Medtronic HQ in Minneapolis, MN.
Roy holds an MBA from the Kellogg School of Management, a master’s degree in engineering management from the McCormick School of Engineering at Northwestern University in Evanston, Illinois, and a B.Sc. in engineering from the Technion in Haifa.
Mr. Dan Lemaitre joined BlueWind Medical as Executive Chairman in September 2018 and serves as CEO since January 2020.
Dan also serves on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$700 million per annum.
Previously, Dan was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. Prior to joining CoreValve, Dan was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development.
Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.
Mrs. Ofri Vaisman is bringing to Bluewind Medical her extensive experience in leading global cross-functional teams in the realization of new medical technologies from the initial concept, through product development, regulatory clearance and commercialization. Prior to joining the Company Ofri was the Director of the Medical Program at Aspect Imaging where she was responsible for the business strategy and product development of a novel Neonatal MRI system. Prior to that, Ofri was the Director of Program Management at Galil Medical (acquired by BTG) directing the development and commercialization of the minimally invasive disposable products. Ofri has also led product and strategic projects at J&J’s Biosense Webster based in California and worked as a consultant to Medical Device start-ups at Ernst & Young. Ofri holds a B.A. (Magna Cum Laude) in Psychology and Science studies from the Hebrew University and an MBA (Summa Cum Laude) from Tel Aviv University.
Dr. Roger Dmochowski is a world-renowned leader in the fields of urology, OAB and incontinence, a recipient of the Zimskind Award and Lifetime Achievement Awards from the Urodynamics Society for his accomplishments in the clinical treatment for incontinence, a Fellow of the American College of Surgeons, a member of the American Urological Association and International Continence Society, and a trustee of the American Board of Urology. An accomplished scholar, Dr. Dmochowski has published over 320 articles, 100 book chapters and 460 abstracts, given over 260 presentations at various national and international meetings, led and participated in dozens of OAB and incontinence studies, is the Editor-in-Chief of NeuroUrology and Urodynamics, and serves on the editorial board for several scientific journals.
Mr. Guri Oron has co-founded Bluewind and been with the company since its inception. He has over 15 years of experience in executive R&D roles, primarily with startups in the medical device field with specific expertise in Neurostimulation technologies. Throughout his career Guri managed complex R&D projects from their ideation through design, engineering, regulatory and clinical development. Prior to working with BlueWind Medical, Guri founded and was the CEO of Cybotech, a multinational financial software company. Early on in his career Guri led the R&D at BrainsGate and served for almost 10 years in the IDF Intelligence Technological Unit. Guri holds a B.Sc. in Electrical Engineering from Tel Aviv University. He is the lead inventor or co-inventor of numerous patent and patent pending applications
Ms. Roni Diaz brings her 24 years of experience in medical device clinical trial management to the table at Bluewind Medical. Prior to joining the company, Roni was Director of Clinical Research at Insightec in Dallas, Texas, where she was responsible for the planning, oversight and organization of US and OUS feasibility, pre-approval, and post-approval studies for a Class III medical device. Before Insightec, Roni was the Global Director of Clinical Affairs for 13 years at Abbott Neuromodulation (formerly St. Jude Medical) in Plano, Texas. She was responsible for oversight of the chronic pain portfolio of studies, including protocol development, study execution, publication planning, and regulatory body submissions. Roni has a B.Sc. in Health Sciences from San Jose State University.
Dr. Karin Aharonson-Raz is a biomedical scientist, trained as a veterinarian doctor and holds a PhD in Epidemiology, with a multidisciplinary research background in neuroscience, immunology and epidemiology. She has been in BlueWind Medical from early stages and was involved as the company transitioned from pre-clinical to clinical phases leading the science research, pre-clinical, clinical and regulatory fields.
Mr. Moshe Ben-Chorin has more than 20 years of experience in the high-tech industry. Prior to joining Bluewind Medical, he served as Vice President of the High-Tech Programs at Ramot, the business engagement center of Tel Aviv University. Before that, he served as VP R&D and headed the system engineering group at Aspect Imaging, where he was involved in the development of medical and pre-clinical MRI systems. Prior to that, Moshe held R&D positions at various companies, including being a co-founder and chief scientist of Genoa Color Technologies, where he guided the development of multi-primary display technology from idea to maturation. Moshe holds a Ph.D. in Physics from the Hebrew University of Jerusalem, and spent several years following graduation in academic research. He is an author of about 60 scientific publications and a co-inventor of more than 20 patent families.
Mr. Dan Lemaitre joined BlueWind Medical as Executive Chairman in September 2018 and serves as CEO since January 2020. Dan also serves on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$700 million per annum. Previously, Dan was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. Prior to joining CoreValve, Dan was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development. Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.
Mr. Neugarten has over 35 years of senior managerial experience, and over 15 years of experience in the medical industry. He brings to BlueWind Medical significant experience in medical devices venture capital investments, commercialization, and asset realization. Mr. Neugarten serves as Executive Chairman of Rainbow Medical, BlueWind’s founding and largest investor. Previously, he was a partner at DOR Ventures, a VC fund focusing on imaging technologies as part of the Viola Partners Group. During his period at DOR Ventures he led various investments including medical imaging ventures. Since 2006, he led the healthcare investments of Viola Partners, and currently serves on the boards of Angioslide, NanoPass, and PainReform. Prior to joining the Viola Partners Group, he worked for Scitex (NASDAQ:SCIX) in various management positions in Europe, Japan, and Israel. He received his BSc in Electronics from the Technion, Haifa Israel, and an MBA from Boston University.
Mr. Cohen brings to BlueWind Medical significant experience in finance, taxes, accounting, and M&As. Mr. Cohen is CFO for Rainbow Medical, BlueWind’s founding and largest investor. Prior to joining Rainbow Medical, Mr. Cohen served as group corporate controller for several companies among them SuperDerivatives Ltd., Verisity Ltd. (NASDAQ: VRST. Mr. Cohen spent four years in public accounting at Kesselman & Kesselman (PwC Israel) in Tel Aviv and PricewaterhouseCoopers in San Jose, California, where he was responsible for hi-tech clients. Mr. Cohen is certified as a CPA in Israel, and holds a BA in economics and accounting and an executive MBA, both from Bar-Ilan University.
Kerry Nelson joined BlueWind Medical as Director in December 2020. She brings expertise in investment and financial management as well as deep experience in investing in medical device companies. Ms. Nelson is currently Portfolio Manager and Founder of Skystone Capital Management LP, which focuses on the healthcare industry. Before starting her own firm, she was a Portfolio Manager at Highbridge Capital Management, a division of JP Morgan Chase & Co. She spent the previous four years as a Partner with Blum Capital Partners LP, an activist fund, where she spearheaded the firm’s healthcare sector activities. From 1995 to 2001, Ms. Nelson was at Fidelity during which she launched and managed the firm’s Medical Technology Fund. She has previously served as a board observer at Haemonetics (NYSE: HAE) and Kinetics Concepts, Inc. (a division of 3M). Nelson earned a BA from Cornell University.
Dr. Heesakkers studied Medicine at the Radboud University of Nijmegen. He started his training in Urology in 1993 at the University Hospital Maastricht. In 1997 he successfully defended his thesis titled: ‘Dynamic Urinary Graciloplasty’ at the University of Maastricht. Since 2000 he is a full-time staff urologist at the Department of Urology of the Radboud UMC and consultant at the Rehabilitation Clinic St Maarten in Nijmegen, the Netherlands. He is heading the Unit of Functional Urology and Neurourology. The Unit is officially recognized as national reference center for functional urological disorders and is part of the European Reference Network, a body of the EU. He is the founder and director of the Nijmegen University Pelvic Care Center Isabella. He chairs the Society of Functional and Reconstructive Urology, a body of the Dutch Association of Urology. Dr. Heesakkers is an active member of the EAU, ICS, SUFU and the AUA. He is a faculty member of the European School of Urology, the Scientific Office of the EAU and the Chairman of the European Section of Female and Functional Urology. Since 2008 he is a principal investigator for the Nijmegen Centre for Molecular Life Sciences. He is an associate editor of Neurourology and Urodynamics and reviewer of several major Urologic Scientific journals. He received about €2.5 million for research grants. He is the author of more than 100 peer-reviewed papers, 5 books and more than 10 book-chapters and books on urological topics.
Director of the Pain Research Unit at the Institute of Pain Medicine, Rambam Health Care Campus and a Professor of Neurology and Pain Medicine at the Faculty of Medicine in the Technion - Institute of Technology, Israel.
Dr. Alex Digesu is a Consultant Obstetrician, Gynaecologist & Urogynaecology Subspecialist at St. Mary’s Hospital, London and Honorary Senior Lecturer at the Imperial College, London. Dr. Digesu completed his specialist training in Obstetrics & Gynaecology and Reproductive Medicine in Italy at the University of Bari in 2002. In 2005 he achieved his PhD in Oncological, Gynaecological and Geriatric Surgery from the same university. His clinical and academic experience also includes a five years fellowship in Urogynaecology in London at King’s College Hospital and St. Mary’s Hospital and two years subspecialty training in Urogynaecology & reconstructive pelvic floor surgery at Imperial College of London. Since 2008 Dr Digesu has also worked as Honorary Senior lecturer in Neurourology, at Beata Vergine Hospital in Mendrisio (Switzerland) where sees and treats lower urinary tract disorders (ie incontinence, voiding problems, urinary retention etc) in patients affected by multiple sclerosis and other neurological diseases. Since 2010 Dr Digesu has been accredited by the Royal College of Obstericians and Gynaecologists as a Specialist in Urogynaecology (specialised in treating patients with bladder & bowel problems such as incontinence and uterovaginal prolapse during pregnancy and after childbirth).
Philip E.V. Van Kerrebroeck is Professor of Urology at the University of Maastricht, and works as a urologist at the Maastricht University Medical Centre, the Netherlands. After obtaining his Medical Degree from the University of Louvain, Belgium, he trained in General Surgery and Urology in Belgium, The Netherlands and the USA. He received his Master’s Degree in Medical Sciences from the University of Antwerp, Belgium, and his PhD in Medicine from the Radboud University of Nijmegen, The Netherlands. Professor Van Kerrebroeck has a long-standing clinical interest in different forms of lower urinary tract problems, both in women and men, including neurogenic bladder dysfunction. His research interests include electrical stimulation of the urinary tract, and the development of new therapies in Neuro-Urology and Functional Urology. Professor Van Kerrebroeck was for 8 years Chairman of the Standardisation Committee of the International Continence Society and was first author of the Standardisation report on Nocturia. He is Fellow of the European Board of Urology. He was involved in the New England Research Institutes Interdisciplinary Conferences on Nocturia and is past Chairman of the ICI-RS Nocturia Think Tank. Professor Van Kerrebroeck is a member of 25 scientific societies; he serves on the editorial board of six journals, and has authored over 265 peer-reviewed articles, book chapters and books. He currently serves as a member of the History Office of the EAU.
Dr. Van Buyten received his doctorate in Medical Science, Surgery and Obstetrics from the Free University of Brussels, Belgium in 1980. From 1980 to 1984, he continued his training in anesthesia and intensive care at the University Hospital in Antwerp, Belgium; in pain therapy at the University Hospital in Gent; in neuroanesthesia at CHU Montpellier, France; and in obstetric anesthesia at the CHU Pitie-Salpetriere Paris, France. In 1997, he graduated with a specialized degree in intensive care medicine.
Dr. Van Buyten is currently the Chairman of the Multidisciplinary Pain Center AZ Nikolaas Sint-Niklaas in Belgium. Dr. Van Buyten is a respected and highly sought-after international lecturer on pain management, and is an active researcher in the field. He has been widely published in many scientific journals, is a member in many prestigious scientific societies—including the Belgian Association for Anesthesia-Reanimation, the European Society Regional Anesthesia, the Flemish Pain Society for Anesthesiologists, and the International Neuromodulation Society.
Howard B. Goldman is a Professor on the faculty of the Cleveland Clinic Lerner College of Medicine and an expert in quality and patient safety serving as the Institute Vice Chairman for Quality at the Glickman Urologic Institute. He has a joint appointment in the departments of urology and obstetrics and gynecology and is actively involved in the training of fellows and residents, including serving as Fellowship director for Female Pelvic Medicine and Reconstructive Surgery in the Department of Urology at the Cleveland Clinic. He has directly trained over 35 fellows and residents who are specialized FPMRS practitioners.
Dr Goldman’s interests are in the medical and surgical treatment of urinary incontinence and other types of voiding dysfunction, neuromodulation, prolapse repair, complex reconstructive female urologic surgery and neurourology. His contributions to the literature have been prolific, including author of over 250 articles and book chapters, editor of three textbooks and panel member for a number of standardization, guidelines and best practice statement panels. Within the AUA he has been on the SUI Guidelines as well as Urodynamics guidelines committees. Within ICS he has been on the male LUTS terminology committee as well as the ICS/IUGA female prolapse terminology committee. He also led the group that came up with the ICS sacral neuromodulation best practices document.
His prominent international reputation has led to invitations as visiting professor in the United States and abroad as well as numerous invited lectures. He is on the editorial board of a number of journals and is a former Assistant Editor of the Journal of Urology. .
He is currently the co-director of the AUA annual review course for part 1 of the ABU exam, is on the AUA Education committee, serves as online education director for IUGA, is the scientific co-chair for the 2020 ICS annual meeting, was the program co-chair for the 2020 SUFU meeting, was on the program committee for the 2020 International Neurourology Society and is the International Consultation on Incontinence committee chair for surgery for male incontinence.
Dr Goldman has been involved in and led numerous projects related to innovative treatments utilizing stem cells for SUI, neuromodulation, utilization of urodynamics, management of complications and improvements in safety and efficiency in pelvic floor surgery.
Dr. Goldman is an astute physician-scientist, nurturing educator, model leader, and unwavering patient advocate renowned in the field of urology.
Dr Richter is The Obstetrics and Gynecology Endowed Chair in the Department of Obstetrics and Gynecology at the University of Alabama at Birmingham (UAB). She is Professor of Obstetrics and Gynecology, Urology & Geriatrics, past Division Director and current Research Director of the Division of Urogynecology and Pelvic Reconstructive Surgery. She is the Medical and Quality Officer of the Ambulatory OB/GYN Clinics and Director of the Urogynecology Care and Genitorectal Disorders Clinics. She is Associate Director of Gynecologic Research for the Center for Women’s Reproductive Health and past President of the Society of Gynecologic Surgeons. She is currently President-elect of the American Urogynecologic Society and serves as an Editor for the International Urogynecology Journal and Obstetrics and Gynecology. In 2019, Dr Richter received the Society of Gynecologic Surgeons Distinguished Surgeon Award. She was the Principal Investigator of the NIDDK-sponsored Urinary Incontinence Treatment Network and is PI of the NICHD-sponsored Pelvic Floor Disorders Network since its inception in 2001. She oversees other NIH (R01) and industry sponsored research. She was also the recipient of a 10 year mid-career award (K24, NIDDK) in patient oriented pelvic floor research and mentors many young investigators. She has over 300 publications, many in top journals such as JAMA and NEJM. Dr. Richter is the ACOG representative to the Section for Enhancing Geriatric Understanding and Expertise among Surgical and Medical Specialists (SEGUE) council of the American Geriatrics Society/Hartford Foundation. She has a strong interest in treating vesicovaginal fistulas and has visited Africa regularly over the past 15 years.
Eric S. Rovner, M.D. is a Professor in the Department of Urology at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. He is the director of the Section of Voiding Dysfunction, Female Urology and Urodynamics in the Department of Urology at MUSC. He is Board Certified in Urology and Female Pelvic Medicine and Reconstructive Surgery, Fellow of the American College of Surgeons, as well as a member of the Society of Pelvic Surgeons, American Association of GU Surgeons, Society of Academic Urologists, and the Society for Urodynamics, Female Urology and Urogenital reconstruction (SUFU) among others. He was the President of SUFU from 2014-16. Dr. Rovner’s research interests include the study of voiding dysfunction, overactive bladder, interstitial cystitis, lower urinary tract reconstruction, neurourology and urodynamics. He has held several visiting professorships and is the author of >150 peer-reviewed scientific articles, and >30 book chapters on these topics as well as books on urinary incontinence and urodynamics. He has been an invited speaker on numerous occasions throughout the United States and the world, and has been the Principal or co-investigator on multiple NIDDK/NIH as well as industry sponsored grants.
Gary Lemack, M.D., is a Professor in the Department of Urology at UT Southwestern Medical Center and is the holder of the Rose Mary Haggar Professorship. He and has a secondary appointment in the Department of Neurology. He is board certified in Urology and Female Pelvic Medicine and Reconstructive Surgery. He has been the Residency Program Director in the Department of Urology since 2004 and is the past Program Director for the Female Pelvic Medicine and Reconstructive Surgery Fellowship. His clinical specialties include urinary incontinence, pelvic organ prolapse, overactive bladder, and voiding dysfunction in the setting of neurologic disease. In particular, he cares for patients with bladder conditions stemming from spinal cord injury, multiple sclerosis, and movement disorders such as Parkinson’s Disease. He performs complex urinary diversions for patients with severe bladder disorders due to congenital and advanced neurological diseases. Dr. Lemack earned his medical degree from Cornell University and performed his residency at The New York Hospital. His fellowship training at UT Southwestern focused on incontinence, urodynamics, and neurourology. Dr. Lemack has been a faculty member at UT Southwestern since 1999. He is also active in research. His clinical research has focused on the use of urodynamic studies in patients with lower urinary tract dysfunction/incontinence, and on establishing best urological practices in the care of patients with multiple sclerosis, spinal cord injury, and other neurological conditions. Texas Monthly has honored Dr. Lemack with its Super Doctor award, and D Magazine has named him a Best Doctor in Dallas on multiple occasions, including 2020. Dr. Lemack is the Past President of the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) – the primary urology subspecialty organization devoted to the conditions affecting the pelvic floor, such as incontinence and prolapse – where he has been on the Executive Committee since 2005. He has earned both the Paul Zimskind and Distinguished Service awards from SUFU, two of the highest honors that the Society bestows. He has been on the Board of the South Central Section of the American Urological Association, and is a former member of the Editorial Board of the Journal of Urology. He is one of 12 Trustees of the American Board of Urology and currently serves at the Chair of the Oral Examination Committee for the Board. Dr. Lemack has authored two guidelines from the American Urological Association (Urodynamics and Stress Urinary Incontinence) and served as the lone American representative on The European Association of Urology Incontinence Guidelines. He has authored over 160 original articles and over 25 book chapters. He has been Visiting Professor at 25 locations throughout the United States, South and Central America and Australia.
Sandip Vasavada, MD, serves as the Urologic Director, Center for Female Urology and Reconstructive Pelvic Surgery, at Cleveland Clinic within the Glickman Urological Institute. Together with his other colleagues he helps represent one of the largest centers for female urology and reconstructive genitourinary surgery in the country. He is also Professor of Surgery (Urology) at the Cleveland Clinic Lerner College of Medicine and has a joint appointment with the Women's Health Institute.
Dr. Vasavada completed his medical school training in the competitive six-year combined BS/MD program at Northeastern Ohio Universities College of Medicine in 1991. Upon graduation, he began his urology residency at Cleveland Clinic and graduated the residency in 1997. Subsequently, he began a fellowship in female urology, neuro-urology and reconstruction at the UCLA School of Medicine in Los Angeles, Calif. He then took a position as Assistant Professor of Urology at Thomas Jefferson Medical College in Philadelphia prior to returning to Cleveland in 2001.
Dr. Vasavada has published numerous manuscripts and book chapters in the area of voiding dysfunction and urinary incontinence and has been named to "Top Docs" in Philadelphia and Cleveland magazines for over 15 years, Crains Cleveland Business Top 40 under 40 and the Urology department Teacher of the Year. He has published three textbooks and has authored over 100 manuscripts and over 25 book chapters and numerous abstracts and videos . He has lectured and demonstrated surgical techniques around the world in over 20 countries. Dr Vasavada is a reviewer for seven major journals in the field of urology, urogynecology and voiding dysfunction. He recently completed a term on task force A of the American Board of Urology Exam Committee and has helped author the American Urological Association (AUA) and Society of Urodynamics and Female Urogenital Reconstruction (SUFU) Guidelines in Overactive Bladder and Stress Urinary Incontinence for the country. Additionally, Dr Vasavada serves presently as Vice President of SUFU.
Dr. Vasavada's main clinical interests lie in the area of urinary incontinence, pelvic organ prolapse and complex reconstruction of the lower urinary tract and management of complications of vaginal and lower urinary tract surgery. His current research interests are in the field of refractory bladder overactivity and neuromodulation and care pathways for optimizing care in patients undergoing incontinence and prolapse surgery. Dr. Vasavada serves with the Section of Urogynecology on the NIH-Pelvic Floor Disorders Network.
Dr. Sidon is a senior physician in the pediatric orthopedic unit in the Schneider's children hospital in Petah-Tikva, Israel. He graduated from Sackler medical school in Tel-aviv university in 2008, and completed his orthopedic training in Beilinson hospital in 2016. He continued his training in the US with a fellowship year in foot and ankle in the Rothman institute and a fellowship year in pediatric orthopedics in the New york Presbyterian Hospital. He is a member of the Israeli orthopedic foot and ankle society, the European foot and ankle society as well as the Israeli Pediatric Orthopedic Society.